Cure8 research brief
People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and regulatory mechanisms tied to genetic risk can guide future therapies and tests.
Researchers studying IBD genetics, single-cell genomics, and drug discovery; clinicians treating patients with TNFi nonresponse; patients on biologics and families of pediatric IBD patients interested in research advances.
This study used single-nuclei multiome sequencing and computational GRN modeling on pediatric intestinal samples to connect noncoding IBD genetic risk variants with cell-type-specific regulatory programs.
Th17 cells and inflammatory monocytes/macrophages were identified as mediators of genetic risk, and distinct TF activities and signaling pathways were associated with TNFi nonresponse. The findings are based on integrated molecular maps and modeling rather than clinical trial results.
The work nominates mechanisms and therapeutic targets (beyond TNF) that merit follow-up in functional studies and clinical research.
Abstract-level findings nominate mechanisms but do not report clinical outcomes or therapeutic efficacy. The study focuses on pediatric intestinal tissue and uses computational colocalization and GRN modeling; experimental and clinical validation are required.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
